

Hematologic Malignancies Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028

<https://marketpublishers.com/r/H8D1FB690B22EN.html>

Date: November 2023

Pages: 148

Price: US\$ 2,499.00 (Single User License)

ID: H8D1FB690B22EN

Abstracts

The global hematologic malignancies market size reached US\$ 55.3 Billion in 2022. Looking forward, IMARC Group expects the market to reach US\$ 93.2 Billion by 2028, exhibiting a growth rate (CAGR) of 9.1% during 2022-2028.

Hematologic malignancies, such as lymphoma, leukemia, and multiple myeloma, are cancers of blood-producing cells. These cells comprise platelets for wound clotting, red blood cells (RBCs) to carry oxygen, and white blood cells (WBCs) for immune protection, which originate from hematopoietic stem and progenitor cells in the bone marrow. Hematologic malignancies can be diagnosed using tests like microscopy, cytogenetics, immunophenotyping, flow cytometry, fluorescence in situ hybridization (FISH), polymerase chain reaction (PCR), and gene expression profiling. Nowadays, several drugs, including antitumor antibiotics, histone deacetylase inhibitors, and Janus kinase (JAK) inhibitors, are available around the world for treatment based on diagnostic tests.

Hematologic Malignancies Market Trends:

The incidence of acute myeloid leukemia (AML) is relatively higher among the geriatric population. This, in confluence with the increasing life expectancy, represents one of the key factors catalyzing the demand for hematologic malignancies drugs across the globe. Besides this, with advances in immunohistochemistry (IHC), hematologic malignancies can be diagnosed accurately by exposing tissue samples to various antibodies directed against cell molecules and antigens. This, in turn, is strengthening the growth of the market. Moreover, the rising awareness about early diagnosis, along with improving diagnostic modalities, is contributing to market growth. Apart from this, surgical therapy is available for tissue diagnosis and treatment of lymphoma complications, such as perforation, obstruction, and stricture. This, in confluence with the launch of several novel therapies and multiple label expansions of premium-priced

agents, such as CAR T-cell therapies and brexucabtagene autoleuce, is propelling the market growth. Furthermore, ongoing clinical research studies to introduce advanced drugs for patients with advanced hematologic malignancies are anticipated to drive the market in the coming years.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global hematologic malignancies market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on type, therapy and end user.

Breakup by Type:

- Leukemia
- Lymphoma
- Multiple Myeloma
- Others

Breakup by Therapy:

- Chemotherapy
- Radiotherapy
- Immunotherapy
- Stem Cell Transplantation
- Others

Breakup by End User:

- Hospitals
- Diagnostics Centers
- Research Centers
- Others

Breakup by Region:

- North America
 - United States
 - Canada
- Asia-Pacific
 - China
 - Japan
 - India
 - South Korea
 - Australia
 - Indonesia
 - Others
- Europe
 - Germany

France
United Kingdom
Italy
Spain
Russia
Others

Latin America
Brazil
Mexico
Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being AbbVie Inc., AstraZeneca plc, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Johnson & Johnson, Merck & Co. Inc, Novartis AG, Pfizer Inc., Sanofi S.A. and Takeda Pharmaceutical Company Limited.

Key Questions Answered in This Report:

How has the global hematologic malignancies market performed so far and how will it perform in the coming years?

What has been the impact of COVID-19 on the global hematologic malignancies market?

What are the key regional markets?

What is the breakup of the market based on the type?

What is the breakup of the market based on the therapy?

What is the breakup of the market based on the end user?

What are the various stages in the value chain of the industry?

What are the key driving factors and challenges in the industry?

What is the structure of the global hematologic malignancies market and who are the key players?

What is the degree of competition in the industry?

Contents

1 PREFACE

2 SCOPE AND METHODOLOGY

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
 - 2.3.1 Primary Sources
 - 2.3.2 Secondary Sources
- 2.4 Market Estimation
 - 2.4.1 Bottom-Up Approach
 - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

3 EXECUTIVE SUMMARY

4 INTRODUCTION

- 4.1 Overview
- 4.2 Key Industry Trends

5 GLOBAL HEMATOLOGIC MALIGNANCIES MARKET

- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast

6 MARKET BREAKUP BY TYPE

- 6.1 Leukemia
 - 6.1.1 Market Trends
 - 6.1.2 Market Forecast
- 6.2 Lymphoma
 - 6.2.1 Market Trends

- 6.2.2 Market Forecast
- 6.3 Multiple Myeloma
 - 6.3.1 Market Trends
 - 6.3.2 Market Forecast
- 6.4 Others
 - 6.4.1 Market Trends
 - 6.4.2 Market Forecast

7 MARKET BREAKUP BY THERAPY

- 7.1 Chemotherapy
 - 7.1.1 Market Trends
 - 7.1.2 Market Forecast
- 7.2 Radiotherapy
 - 7.2.1 Market Trends
 - 7.2.2 Market Forecast
- 7.3 Immunotherapy
 - 7.3.1 Market Trends
 - 7.3.2 Market Forecast
- 7.4 Stem Cell Transplantation
 - 7.4.1 Market Trends
 - 7.4.2 Market Forecast
- 7.5 Others
 - 7.5.1 Market Trends
 - 7.5.2 Market Forecast

8 MARKET BREAKUP BY END USER

- 8.1 Hospitals
 - 8.1.1 Market Trends
 - 8.1.2 Market Forecast
- 8.2 Diagnostics Centers
 - 8.2.1 Market Trends
 - 8.2.2 Market Forecast
- 8.3 Research Centers
 - 8.3.1 Market Trends
 - 8.3.2 Market Forecast
- 8.4 Others
 - 8.4.1 Market Trends

8.4.2 Market Forecast

9 MARKET BREAKUP BY REGION

9.1 North America

9.1.1 United States

9.1.1.1 Market Trends

9.1.1.2 Market Forecast

9.1.2 Canada

9.1.2.1 Market Trends

9.1.2.2 Market Forecast

9.2 Asia-Pacific

9.2.1 China

9.2.1.1 Market Trends

9.2.1.2 Market Forecast

9.2.2 Japan

9.2.2.1 Market Trends

9.2.2.2 Market Forecast

9.2.3 India

9.2.3.1 Market Trends

9.2.3.2 Market Forecast

9.2.4 South Korea

9.2.4.1 Market Trends

9.2.4.2 Market Forecast

9.2.5 Australia

9.2.5.1 Market Trends

9.2.5.2 Market Forecast

9.2.6 Indonesia

9.2.6.1 Market Trends

9.2.6.2 Market Forecast

9.2.7 Others

9.2.7.1 Market Trends

9.2.7.2 Market Forecast

9.3 Europe

9.3.1 Germany

9.3.1.1 Market Trends

9.3.1.2 Market Forecast

9.3.2 France

9.3.2.1 Market Trends

- 9.3.2.2 Market Forecast
- 9.3.3 United Kingdom
 - 9.3.3.1 Market Trends
 - 9.3.3.2 Market Forecast
- 9.3.4 Italy
 - 9.3.4.1 Market Trends
 - 9.3.4.2 Market Forecast
- 9.3.5 Spain
 - 9.3.5.1 Market Trends
 - 9.3.5.2 Market Forecast
- 9.3.6 Russia
 - 9.3.6.1 Market Trends
 - 9.3.6.2 Market Forecast
- 9.3.7 Others
 - 9.3.7.1 Market Trends
 - 9.3.7.2 Market Forecast
- 9.4 Latin America
 - 9.4.1 Brazil
 - 9.4.1.1 Market Trends
 - 9.4.1.2 Market Forecast
 - 9.4.2 Mexico
 - 9.4.2.1 Market Trends
 - 9.4.2.2 Market Forecast
 - 9.4.3 Others
 - 9.4.3.1 Market Trends
 - 9.4.3.2 Market Forecast
- 9.5 Middle East and Africa
 - 9.5.1 Market Trends
 - 9.5.2 Market Breakup by Country
 - 9.5.3 Market Forecast

10 SWOT ANALYSIS

- 10.1 Overview
- 10.2 Strengths
- 10.3 Weaknesses
- 10.4 Opportunities
- 10.5 Threats

11 VALUE CHAIN ANALYSIS

12 PORTERS FIVE FORCES ANALYSIS

- 12.1 Overview
- 12.2 Bargaining Power of Buyers
- 12.3 Bargaining Power of Suppliers
- 12.4 Degree of Competition
- 12.5 Threat of New Entrants
- 12.6 Threat of Substitutes

13 PRICE ANALYSIS

14 COMPETITIVE LANDSCAPE

- 14.1 Market Structure
- 14.2 Key Players
- 14.3 Profiles of Key Players
 - 14.3.1 AbbVie Inc.
 - 14.3.1.1 Company Overview
 - 14.3.1.2 Product Portfolio
 - 14.3.1.3 Financials
 - 14.3.1.4 SWOT Analysis
 - 14.3.2 AstraZeneca plc
 - 14.3.2.1 Company Overview
 - 14.3.2.2 Product Portfolio
 - 14.3.2.3 Financials
 - 14.3.2.4 SWOT Analysis
 - 14.3.3 Bristol-Myers Squibb Company
 - 14.3.3.1 Company Overview
 - 14.3.3.2 Product Portfolio
 - 14.3.3.3 Financials
 - 14.3.3.4 SWOT Analysis
 - 14.3.4 Eli Lilly and Company
 - 14.3.4.1 Company Overview
 - 14.3.4.2 Product Portfolio
 - 14.3.4.3 Financials

- 14.3.4.4 SWOT Analysis
- 14.3.5 F. Hoffmann-La Roche Ltd
 - 14.3.5.1 Company Overview
 - 14.3.5.2 Product Portfolio
 - 14.3.5.3 Financials
- 14.3.6 GlaxoSmithKline plc
 - 14.3.6.1 Company Overview
 - 14.3.6.2 Product Portfolio
 - 14.3.6.3 Financials
 - 14.3.6.4 SWOT Analysis
- 14.3.7 Johnson & Johnson
 - 14.3.7.1 Company Overview
 - 14.3.7.2 Product Portfolio
 - 14.3.7.3 Financials
 - 14.3.7.4 SWOT Analysis
- 14.3.8 Merck & Co. Inc
 - 14.3.8.1 Company Overview
 - 14.3.8.2 Product Portfolio
 - 14.3.8.3 Financials
 - 14.3.8.4 SWOT Analysis
- 14.3.9 Novartis AG
 - 14.3.9.1 Company Overview
 - 14.3.9.2 Product Portfolio
 - 14.3.9.3 Financials
 - 14.3.9.4 SWOT Analysis
- 14.3.10 Pfizer Inc.
 - 14.3.10.1 Company Overview
 - 14.3.10.2 Product Portfolio
 - 14.3.10.3 Financials
 - 14.3.10.4 SWOT Analysis
- 14.3.11 Sanofi S.A.
 - 14.3.11.1 Company Overview
 - 14.3.11.2 Product Portfolio
 - 14.3.11.3 Financials
 - 14.3.11.4 SWOT Analysis
- 14.3.12 Takeda Pharmaceutical Company Limited
 - 14.3.12.1 Company Overview
 - 14.3.12.2 Product Portfolio
 - 14.3.12.3 Financials

14.3.12.4 SWOT Analysis

List Of Tables

LIST OF TABLES

Table 1: Global: Hematologic Malignancies Market: Key Industry Highlights, 2022 and 2028

Table 2: Global: Hematologic Malignancies Market Forecast: Breakup by Type (in Million US\$), 2023-2028

Table 3: Global: Hematologic Malignancies Market Forecast: Breakup by Therapy (in Million US\$), 2023-2028

Table 4: Global: Hematologic Malignancies Market Forecast: Breakup by End User (in Million US\$), 2023-2028

Table 5: Global: Hematologic Malignancies Market Forecast: Breakup by Region (in Million US\$), 2023-2028

Table 6: Global: Hematologic Malignancies Market: Competitive Structure

Table 7: Global: Hematologic Malignancies Market: Key Players

List Of Figures

LIST OF FIGURES

Figure 1: Global: Hematologic Malignancies Market: Major Drivers and Challenges

Figure 2: Global: Hematologic Malignancies Market: Sales Value (in Billion US\$), 2017-2022

Figure 3: Global: Hematologic Malignancies Market Forecast: Sales Value (in Billion US\$), 2023-2028

Figure 4: Global: Hematologic Malignancies Market: Breakup by Type (in %), 2022

Figure 5: Global: Hematologic Malignancies Market: Breakup by Therapy (in %), 2022

Figure 6: Global: Hematologic Malignancies Market: Breakup by End User (in %), 2022

Figure 7: Global: Hematologic Malignancies Market: Breakup by Region (in %), 2022

Figure 8: Global: Hematologic Malignancies (Leukemia) Market: Sales Value (in Million US\$), 2017 & 2022

Figure 9: Global: Hematologic Malignancies (Leukemia) Market Forecast: Sales Value (in Million US\$), 2023-2028

Figure 10: Global: Hematologic Malignancies (Lymphoma) Market: Sales Value (in Million US\$), 2017 & 2022

Figure 11: Global: Hematologic Malignancies (Lymphoma) Market Forecast: Sales Value (in Million US\$), 2023-2028

Figure 12: Global: Hematologic Malignancies (Multiple Myeloma) Market: Sales Value (in Million US\$), 2017 & 2022

Figure 13: Global: Hematologic Malignancies (Multiple Myeloma) Market Forecast: Sales Value (in Million US\$), 2023-2028

Figure 14: Global: Hematologic Malignancies (Other Types) Market: Sales Value (in Million US\$), 2017 & 2022

Figure 15: Global: Hematologic Malignancies (Other Types) Market Forecast: Sales Value (in Million US\$), 2023-2028

Figure 16: Global: Hematologic Malignancies (Chemotherapy) Market: Sales Value (in Million US\$), 2017 & 2022

Figure 17: Global: Hematologic Malignancies (Chemotherapy) Market Forecast: Sales Value (in Million US\$), 2023-2028

Figure 18: Global: Hematologic Malignancies (Radiotherapy) Market: Sales Value (in Million US\$), 2017 & 2022

Figure 19: Global: Hematologic Malignancies (Radiotherapy) Market Forecast: Sales Value (in Million US\$), 2023-2028

Figure 20: Global: Hematologic Malignancies (Immunotherapy) Market: Sales Value (in Million US\$), 2017 & 2022

- Figure 21: Global: Hematologic Malignancies (Immunotherapy) Market Forecast: Sales Value (in Million US\$), 2023-2028
- Figure 22: Global: Hematologic Malignancies (Stem Cell Transplantation) Market: Sales Value (in Million US\$), 2017 & 2022
- Figure 23: Global: Hematologic Malignancies (Stem Cell Transplantation) Market Forecast: Sales Value (in Million US\$), 2023-2028
- Figure 24: Global: Hematologic Malignancies (Other Therapies) Market: Sales Value (in Million US\$), 2017 & 2022
- Figure 25: Global: Hematologic Malignancies (Other Therapies) Market Forecast: Sales Value (in Million US\$), 2023-2028
- Figure 26: Global: Hematologic Malignancies (Hospitals) Market: Sales Value (in Million US\$), 2017 & 2022
- Figure 27: Global: Hematologic Malignancies (Hospitals) Market Forecast: Sales Value (in Million US\$), 2023-2028
- Figure 28: Global: Hematologic Malignancies (Diagnostics Centers) Market: Sales Value (in Million US\$), 2017 & 2022
- Figure 29: Global: Hematologic Malignancies (Diagnostics Centers) Market Forecast: Sales Value (in Million US\$), 2023-2028
- Figure 30: Global: Hematologic Malignancies (Research Centers) Market: Sales Value (in Million US\$), 2017 & 2022
- Figure 31: Global: Hematologic Malignancies (Research Centers) Market Forecast: Sales Value (in Million US\$), 2023-2028
- Figure 32: Global: Hematologic Malignancies (Other End Users) Market: Sales Value (in Million US\$), 2017 & 2022
- Figure 33: Global: Hematologic Malignancies (Other End Users) Market Forecast: Sales Value (in Million US\$), 2023-2028
- Figure 34: North America: Hematologic Malignancies Market: Sales Value (in Million US\$), 2017 & 2022
- Figure 35: North America: Hematologic Malignancies Market Forecast: Sales Value (in Million US\$), 2023-2028
- Figure 36: United States: Hematologic Malignancies Market: Sales Value (in Million US\$), 2017 & 2022
- Figure 37: United States: Hematologic Malignancies Market Forecast: Sales Value (in Million US\$), 2023-2028
- Figure 38: Canada: Hematologic Malignancies Market: Sales Value (in Million US\$), 2017 & 2022
- Figure 39: Canada: Hematologic Malignancies Market Forecast: Sales Value (in Million US\$), 2023-2028
- Figure 40: Asia-Pacific: Hematologic Malignancies Market: Sales Value (in Million US\$),

2017 & 2022

Figure 41: Asia-Pacific: Hematologic Malignancies Market Forecast: Sales Value (in Million US\$), 2023-2028

Figure 42: China: Hematologic Malignancies Market: Sales Value (in Million US\$), 2017 & 2022

Figure 43: China: Hematologic Malignancies Market Forecast: Sales Value (in Million US\$), 2023-2028

Figure 44: Japan: Hematologic Malignancies Market: Sales Value (in Million US\$), 2017 & 2022

Figure 45: Japan: Hematologic Malignancies Market Forecast: Sales Value (in Million US\$), 2023-2028

Figure 46: India: Hematologic Malignancies Market: Sales Value (in Million US\$), 2017 & 2022

Figure 47: India: Hematologic Malignancies Market Forecast: Sales Value (in Million US\$), 2023-2028

Figure 48: South Korea: Hematologic Malignancies Market: Sales Value (in Million US\$), 2017 & 2022

Figure 49: South Korea: Hematologic Malignancies Market Forecast: Sales Value (in Million US\$), 2023-2028

Figure 50: Australia: Hematologic Malignancies Market: Sales Value (in Million US\$), 2017 & 2022

Figure 51: Australia: Hematologic Malignancies Market Forecast: Sales Value (in Million US\$), 2023-2028

Figure 52: Indonesia: Hematologic Malignancies Market: Sales Value (in Million US\$), 2017 & 2022

Figure 53: Indonesia: Hematologic Malignancies Market Forecast: Sales Value (in Million US\$), 2023-2028

Figure 54: Others: Hematologic Malignancies Market: Sales Value (in Million US\$), 2017 & 2022

Figure 55: Others: Hematologic Malignancies Market Forecast: Sales Value (in Million US\$), 2023-2028

Figure 56: Europe: Hematologic Malignancies Market: Sales Value (in Million US\$), 2017 & 2022

Figure 57: Europe: Hematologic Malignancies Market Forecast: Sales Value (in Million US\$), 2023-2028

Figure 58: Germany: Hematologic Malignancies Market: Sales Value (in Million US\$), 2017 & 2022

Figure 59: Germany: Hematologic Malignancies Market Forecast: Sales Value (in Million US\$), 2023-2028

Figure 60: France: Hematologic Malignancies Market: Sales Value (in Million US\$), 2017 & 2022

Figure 61: France: Hematologic Malignancies Market Forecast: Sales Value (in Million US\$), 2023-2028

Figure 62: United Kingdom: Hematologic Malignancies Market: Sales Value (in Million US\$), 2017 & 2022

Figure 63: United Kingdom: Hematologic Malignancies Market Forecast: Sales Value (in Million US\$), 2023-2028

Figure 64: Italy: Hematologic Malignancies Market: Sales Value (in Million US\$), 2017 & 2022

Figure 65: Italy: Hematologic Malignancies Market Forecast: Sales Value (in Million US\$), 2023-2028

Figure 66: Spain: Hematologic Malignancies Market: Sales Value (in Million US\$), 2017 & 2022

Figure 67: Spain: Hematologic Malignancies Market Forecast: Sales Value (in Million US\$), 2023-2028

Figure 68: Russia: Hematologic Malignancies Market: Sales Value (in Million US\$), 2017 & 2022

Figure 69: Russia: Hematologic Malignancies Market Forecast: Sales Value (in Million US\$), 2023-2028

Figure 70: Others: Hematologic Malignancies Market: Sales Value (in Million US\$), 2017 & 2022

Figure 71: Others: Hematologic Malignancies Market Forecast: Sales Value (in Million US\$), 2023-2028

Figure 72: Latin America: Hematologic Malignancies Market: Sales Value (in Million US\$), 2017 & 2022

Figure 73: Latin America: Hematologic Malignancies Market Forecast: Sales Value (in Million US\$), 2023-2028

Figure 74: Brazil: Hematologic Malignancies Market: Sales Value (in Million US\$), 2017 & 2022

Figure 75: Brazil: Hematologic Malignancies Market Forecast: Sales Value (in Million US\$), 2023-2028

Figure 76: Mexico: Hematologic Malignancies Market: Sales Value (in Million US\$), 2017 & 2022

Figure 77: Mexico: Hematologic Malignancies Market Forecast: Sales Value (in Million US\$), 2023-2028

Figure 78: Others: Hematologic Malignancies Market: Sales Value (in Million US\$), 2017 & 2022

Figure 79: Others: Hematologic Malignancies Market Forecast: Sales Value (in Million

US\$), 2023-2028

Figure 80: Middle East and Africa: Hematologic Malignancies Market: Sales Value (in Million US\$), 2017 & 2022

Figure 81: Middle East and Africa: Hematologic Malignancies Market: Breakup by Country (in %), 2022

Figure 82: Middle East and Africa: Hematologic Malignancies Market Forecast: Sales Value (in Million US\$), 2023-2028

Figure 83: Global: Hematologic Malignancies Industry: SWOT Analysis

Figure 84: Global: Hematologic Malignancies Industry: Value Chain Analysis

Figure 85: Global: Hematologic Malignancies Industry: Porter's Five Forces Analysis

I would like to order

Product name: Hematologic Malignancies Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028

Product link: <https://marketpublishers.com/r/H8D1FB690B22EN.html>

Price: US\$ 2,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/H8D1FB690B22EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

